

■ **Swissmedic has approved once-monthly, oral ibandronic acid** [Bonviva; Roche, GlaxoSmithKline] 150mg for the treatment of postmenopausal osteoporosis. The product is the first ever oral treatment administered as one tablet once a month for any disease.

Roche, et al. Once-Monthly Oral Bonviva Approved for Postmenopausal Osteoporosis in Switzerland. Media Release : 8 Sep 2005. Available from:
URL: <http://www.roche.com> 809054151